TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22892773
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml saline solution of Propionium bacterium parvum, one dose a month for 3 to 5 months
Study: 22892773
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml intradermal injection of placebo solution
Study: 27117753
Drug: Desmopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.3 μg/kg in saline solution)
Study: 23636302
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg, n=42)
Study: 23636302
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (4 mg, n=24)
Study: 18096304
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of Sonazoid (0.6 microL microbubbles/kg body weight)
Study: 18096304
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of Sonazoid (1.2 microL microbubbles/kg body weight over 30 min)
Study: 18096304
Drug: Both bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both bolus injection and continuous infusion of Sonazoid
Study: 12816354
Drug: Group E:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E: 1.5 mL/kg, 370 mgI/mL, 5 mL/sec
Study: 12816354
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 100 ml, 300 mgI/mL, 3 mL/sec
Study: 12816354
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 2 mL/kg, 300 mgI/mL, 3 mL/sec
Study: 12816354
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 1.5 mL/kg, 370 mgI/mL, 3 mL/sec
Study: 12816354
Drug: Group D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D: 2 mL/kg, 300 mgI/mL, 5 mL/sec
Study: 7847251
Drug: Superselective carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Superselective carboplatin (200 mg/m2 and 300 mg/m2) with concurrent infusional 5-fluorouracil (225 mg/m2) and radiotherapy
Study: 30968444
Drug: 500 U
Normalized name: lipase 4500 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 U C1‐INH, twice weekly for 12 weeks
Study: 30968444
Drug: 1000 U
Normalized name: lipase 1000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 U C1‐INH, twice weekly for 12 weeks
Study: 30968444
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of C1‐INH
Study: 19058059
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of 17beta-estradiol
Study: 9490625
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against IgE and IgD; tested using ELISA with peroxidase conjugated antibodies.
Study: 9490625
Drug: Specific IgG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific IgG, IgM, and IgA antibodies with polysaccharide from Neisseria meningitidis serotype A; studied during vaccine testing.
Study: 8195853
Drug: Brodimoprim (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim (10 mg/kg on the first day, 5 mg/kg/day thereafter)
Study: 8195853
Drug: Erythromycin (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (560 mg/kg/8 hours)
Study: 8195853
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid (50 mg/kg/12 hours)
Study: 8195853
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (Erythromycin and Amoxicillin/clavulanic acid)
Study: 3099313
Drug: Enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (35 mcg) administered 25 min before a meal (anti-cibum AC)
Study: 3099313
Drug: Enprostil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil (35 mcg) administered 5 min after a meal (post-cibum PC)
Study: 3099313
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 25 min before a meal (anti-cibum AC)
Study: 3099313
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 5 min after a meal (post-cibum PC)
Study: 19651631
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose PPI therapy
Study: 19651631
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose PPI therapy
Study: 19651631
Drug: Gastrin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin (1 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Study: 19651631
Drug: Gastrin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin (100 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Study: 12085041
Drug: Magnesium Citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium Citrate (Mg)
Study: 12085041
Drug: Sodium Phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Phosphate (NaP) diluted into 3 doses 10 minutes apart
Study: 2195862
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion for 48 hours
Study: 29750828
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg once monthly for 12 months
Study: 15616025
Drug: Beta-cell function
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-cell function adjusted for insulin resistance
Study: 15616025
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FPG > or =5.6 mmol/l, BMI > or =30 kg/m(2), and family history of diabetes
Study: 15616025
Drug: FPG >
Normalized name: Fampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FPG > or =6.1 mmol/l or 2-h glucose > or =7.8 mmol/l
Study: 2698394
Drug: Lactate infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate infusion in MVA patients
Study: 25935960
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/day (Control)
Study: 16046381
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy (60 degrees C far-infrared ray dry sauna for 15 minutes, followed by bed rest with a blanket for 30 minutes, once a day, 5 days a week for 20 sessions in 4 weeks)
Study: 16046381
Drug: Nonthermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonthermal therapy (control group)
Study: 9860109
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg administered orally at 0700 and 1600 hours on days 3, 4, and 5)
Study: 7895560
Drug: Ranitidine (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (6.25 mg/hr continuous infusion)
Study: 23489
Drug: Clorazepate (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate (15 mg at night)
Study: 355663
Drug: Diazepam (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (5 mg three times a day)
Study: 25037854
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) concentrations <8 mg/l
Study: 25037854
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) concentrations 8-19 mg/l
Study: 25037854
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) concentrations >20 mg/l
Study: 22643937
Drug: Levobupivacaine solution
Normalized name: levobupivacaine Injectable Solution
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine solution
Study: 8991488
Drug: MK-462 IV
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 IV doses of 5-90 micrograms kg-1
Study: 8991488
Drug: MK-462 IV
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 IV doses of 60-90 micrograms kg-1
Study: 8991488
Drug: MK-462 oral
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 oral 40 mg tablet without breakfast
Study: 8991488
Drug: MK-462 oral
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-462 oral 40 mg tablet with standard breakfast
Study: 1481177
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at 2 l/min
Study: 1481177
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at 4 l/min
Study: 1481177
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen at 6 l/min
Study: 18695809
Drug: Liquid petroleum
Normalized name: liquid petroleum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid petroleum jelly (30 ml applied in the perineal region during the expulsive period)
Study: 15991506
Drug: Remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil with a small dose of piritramide (0.1 mg kg(‐1))
Study: 8251280
Drug: tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 5 mg
Study: 8815566
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) nadroparin with graduated compression stockings
Study: 28266821
Drug: Amoxapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxapine (50 mg daily for 4 weeks)
Study: 28266821
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (500 μg three-times daily for 4 weeks)
Study: 12081816
Drug: Ground beef
Normalized name: Beef
DrugBank: Beef (DB10509)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground beef with 2.7 g of phytosterols
Study: 9607230
Drug: Self-administered teaching
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered teaching programme (self-training)
Study: 29530346
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery with intraperitoneal chemotherapy (CRS + IPC)
Study: 27649961
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 660 nm, spatial average energy fluency (SAEF) = 1.06 J/cm2, applied on postoperative days 2, 4, 6, and 8.
Study: 27649961
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (details not specified).
Study: 24315980
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without specific physical training, receiving respiratory therapy over 12 weeks.
Study: 22475741
Drug: Aerosolized fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized fluticasone 880 μg twice daily for 6 weeks
Study: 22475741
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler twice daily for 6 weeks
Study: 20576092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate, sulfasalazine, and hydroxychloroquine with prednisolone (FIN‐RACo)
Study: 12406334
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg pimecrolimus twice daily
Study: 12406334
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pimecrolimus twice daily
Study: 8217026
Drug: lisinopril or
Normalized name: lisinopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril or isradipine
Study: 3121861
Drug: Bupropion hydrochloride,
Normalized name: BuPROPion Hydrochloride, 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion hydrochloride, 225-450 mg/day
Study: 29700636
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with hematopoietic stem cell rescue, modified regimen including melphalan, carboplatin, and etoposide.
Study: 29700636
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (initial regimen before modification).
Study: 29700636
Drug: Modified high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified high-dose chemotherapy regimen.
Study: 24925270
Drug: MD supplemented
Normalized name: miconazole nitrate Topical Solution [Nail MD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD supplemented with 30 g/d of nuts (MD+Nuts)
Study: 20724431
Drug: i.v. cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. cyclophosphamide (CYC) 0.5 g/m2 at 4-week intervals with low-dose prednisolone
Study: 20724431
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone alone
Study: 15728070
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 100 microg
Study: 12637258
Drug: Postprandial glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial glucose profile (glucose peaked at 11.2 ± 0.5 mmol/l)
Study: 8852389
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sematilide HCl intravenous infusion over 30 minutes
Study: 8852389
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sematilide HCl tablet
Study: 8852389
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and oral administration of sematilide HCl
Study: 1399032
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg daily for 14 weeks)
Study: 3893014
Drug: Diazepam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.08 mg/kg
Study: 30265691
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (daily multi-strain capsule containing Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, Bifidobacterium lactis B1-04)
Study: 6724070
Drug: Acyclovir cream
Normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir cream
Study: 15759526
Drug: Lower leg
Normalized name: CAPSAICIN 0.18 g in 100 g TOPICAL CLOTH [Nufabrx Lower Leg Sleeve]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower leg casting plus injections with botulinum toxin (group III)
Study: 15759526
Drug: Lower leg
Normalized name: CAPSAICIN 0.18 g in 100 g TOPICAL CLOTH [Nufabrx Lower Leg Sleeve]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower leg casting plus injections with saline (group II)
Study: 15759526
Drug: Current physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current physical treatment (group I)
Study: 11831530
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (no intervention)
Study: 9920138
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at supraphysiological dosages (up to 8 IU/m2/d) for 4 years in the dose-response study.
Study: 9920138
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a total dose of 6 IU/m2/d with low-dose ethinyl estradiol (50 ng/kg/d orally) in once-daily (OD) and twice-daily (BID) injection regimens for 2 years in the frequency-response study.
Study: 9920138
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with healthy Dutch control subjects in the dose-response study.
Study: 9920138
Drug: Increasing GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing GH dosage in the dose-response study.
Study: 9920138
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at supraphysiological dosages.
Study: 7755523
Drug: Cognitive Analytical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Analytical Therapy
Study: 7755523
Drug: Educational Behavioral
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational Behavioral Treatment
Study: 355663
Drug: Cyclobenzaprine hydrochloride
Normalized name: Cyclobenzaprine Hydrochloride
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclobenzaprine hydrochloride (10 mg three times a day)
Study: 31009099
Drug: Outcome studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outcome studies of root canal treatment (n=35)
Study: 25616430
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 300 mg/m(2) on day 1 every 3 weeks
Study: 25616430
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC of 6 on day 1 and nab-paclitaxel 100 mg/m(2) on days 1, 8, and 15 every 21 days
Study: 18697848
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health counseling and dental exam at baseline, followed by randomization and follow-up visits at 9, 12, 18, 24, 30, and 36 months postpartum.
Study: 8852909
Drug: PRP-T conjugate
Normalized name: Haemophilus influenzae type b vaccine, PRP-T conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T conjugate vaccine
Study: 8852909
Drug: Diphtheria-tetanus-pertussis vaccine
Normalized name: DIPHTHERIA/TETANUS/PERTUSSIS VACCINE INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus-pertussis vaccine
Study: 6359843
Drug: Propranolol (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (240 mg daily)
Study: 6872409
Drug: Metoprolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (300 mg daily)
Study: 18936218
Drug: 200 mg/d
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Study: 18936218
Drug: 400 mg/d
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Study: 18936218
Drug: (n‐3) LCPUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (n‐3) LCPUFA alone (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Study: 12756020
Drug: VAD combined
Normalized name: VAD-044
DrugBank: VAD-044 (DB17697)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD combined with fludarabine (25 mg/m2/day i.v. for 5 days)
Study: 10963641
Drug: Cyclophosphamide, methotrexate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, methotrexate, and fluorouracil (CMF) adjuvant therapy
Study: 10963641
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after surgery +/‐ radiotherapy (Control)
Study: 8797150
Drug: L-arginine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 20 g/day
Study: 8797150
Drug: L-arginine 10
Normalized name: RITE AID L-Arginine 1000mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 10 microM
Study: 26582396
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment (n=87)
Study: 25093169
Drug: Intensified and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified and modulated adjuvant treatment with a minimum dose of 64.8 Gy, higher doses of 70.2 Gy (85.4%), pelvic lymph nodes irradiation (57.7%), and/or hormonal therapy (69.1%)
Study: 16186073
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (HRT)
Study: 6624767
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home glucose monitoring
Study: 6624767
Drug: Weekly venipuncture
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly venipuncture protocol
Study: 29264836
Drug: Vorinostat (VOR)
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat (VOR) 200 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Study: 29264836
Drug: Vorinostat (VOR)
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat (VOR) 400 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Study: 26519119
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise prescription
Study: 22484341
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral therapy for insomnia and osteoarthritis pain (CBT‐PI)
Study: 22484341
Drug: Group cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive‐behavioral therapy for osteoarthritis pain alone (CBT‐P)
Study: 20849619
Drug: Care as
Normalized name: TopCare Aspirin 325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care as usual with the addition of occupational therapy